Drugs / ADXS11-001
ADXS11-001
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02164461 | Mar 2015 → Mar 2017 | cervical adenosquamous carcinoma, cervical small cell carcinoma, immunotherapy induced hypophysitis | Advaxis, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01598792 | Feb 2012 → Nov 2014 | oropharyngeal carcinoma | University of Liverpool | Terminated | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02291055 | Apr 2015 → Jul 2019 | cervical cancer, head and neck cancer | Advaxis, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT01671488 | Feb 2013 → Feb 2018 | anal carcinoma | Brown University | Terminated | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT02531854 | Dec 2018 → Mar 2019 | non-small cell lung carcinoma | Advaxis, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT02399813 | Jun 2016 → Jan 2019 | anus cancer | Advaxis, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02002182 | Dec 2013 → Jul 2018 | oropharynx squamous cell carcinoma | Andrew Sikora | Completed | No outcome recorded |
| Phase 2 | NCT01266460 | May 2011 → Oct 2018 | cervical adenosquamous carcinoma | Gynecologic Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT01116245 | Apr 2010 → Dec 2013 | cervical intraepithelial neoplasia | Advaxis, Inc. | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02853604 | Dec 2015 → Jul 2019 | cervical cancer | Advaxis, Inc. | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADXS11-001 | “ADXS11-001 will be given at a dose of 1x109 cfu intravenously once every 28 days for 4 total doses.” NCT01671488 ↗ |
| Known as | ADXS-HPV | “We studied the therapeutic vaccine, Axalimogene filolisbac (ADXS-HPV), in women who had progressed following at least one prior line of therapy” PMID 32641240 ↗ Jul 20201“Two vaccinations with ADXS11-001 (ADXS-HPV) will be given at a dose of 1x10\^9 cfu intravenously.” NCT02002182 ↗ |
| Known as | Axalimogene filolisbac | “We studied the therapeutic vaccine, Axalimogene filolisbac (ADXS-HPV), in women who had progressed following at least one prior line of therapy” PMID 32641240 ↗ Jul 2020 |
| Known as | Lm-LLO-E7 | “ADXS11-001 (Lm-LLO-E7)” NCT01116245 ↗ |
| Modality | Vaccine | “The purpose of this study is to see if an experimental vaccine, ADXS11-001, is effective in stimulating the body's defense system against HPV-positive oropharyngeal squamous...” NCT02002182 ↗ |
| Route | Intravenous | “5x10\^7 cfu x 3 intravenous infusions at 28 day intervals.” NCT01116245 ↗ |